Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
Rhea-AI Summary
Citius Oncology (Nasdaq: CTOR) will attend the USCLC Annual Workshop on March 26, 2026 in Denver to discuss cutaneous T‑cell lymphoma (CTCL) care and clinical experience with LYMPHIR™ (denileukin diftitox‑cxdl), which the company recently launched in the U.S. The team will hold one‑on‑one meetings with CTCL specialists.
Positive
- None.
Negative
- None.
News Market Reaction – CTXR
On the day this news was published, CTXR declined 5.48%, reflecting a notable negative market reaction. Argus tracked a trough of -4.2% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $923K from the company's valuation, bringing the market cap to $16M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CTXR was down 2.52% pre-news while close peers showed mixed moves (e.g., LSTA down 0.2%, ELEV down 2.28%, HOTH up 2.03%, QTTB up 2.58%). Momentum scanner peers also moved both up and down, indicating stock-specific dynamics rather than a sector-wide rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Clinical data update | Positive | +11.0% | Positive Phase 1 topline LYMPHIR data in gynecologic cancers with no new safety issues. |
| Mar 04 | Clinical data update | Positive | +10.3% | Preliminary Phase 1 LYMPHIR data before CAR‑T in high‑risk DLBCL showing high ORR. |
| Feb 24 | Financing / grant | Positive | +12.7% | $3.8M non‑dilutive funding via New Jersey NOL program to support LYMPHIR launch. |
| Feb 13 | Earnings & launch | Positive | -3.5% | First reported LYMPHIR revenue and Q1 2026 results for Citius Pharmaceuticals. |
| Feb 13 | Earnings & launch | Positive | -3.5% | First reported LYMPHIR revenue and Q1 2026 results for Citius Oncology. |
Recent CTXR/CTOR news around LYMPHIR clinical data and non-dilutive funding has often coincided with double-digit gains, while first revenue/quarterly updates saw negative reactions despite positive operational milestones.
Over recent months, Citius and Citius Oncology have transitioned LYMPHIR into a commercial-stage asset, reporting first revenues of $3.9 million for the quarter ended Dec 31, 2025 and securing $3.8 million in non-dilutive funding to support launch activities. Parallel clinical updates in early March 2026 highlighted encouraging Phase 1 data for LYMPHIR in both gynecologic cancers and high‑risk DLBCL, each prompting double‑digit price gains. Against this backdrop, today’s workshop participation underscores continued physician engagement and scientific positioning rather than a new financial or efficacy inflection point.
Market Pulse Summary
The stock moved -5.5% in the session following this news. A negative reaction despite the neutral-to-positive nature of this conference-related news would fit prior divergence where shares fell 3.55% around otherwise constructive LYMPHIR revenue updates. The announcement focuses on clinician engagement rather than new efficacy or financial data, so traders may discount it against balance sheet and going-concern disclosures in recent filings. Historically, the stock has responded more strongly to clear clinical or funding catalysts than to general visibility events.
Key Terms
cutaneous T-cell lymphoma medical
biomarkers medical
radiology medical
digital pathology medical
AI-generated analysis. Not financial advice.
Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinical engagement; one-on-one meetings available
The United States Cutaneous Lymphoma Consortium (USCLC) Annual Workshop is widely regarded as one of the most focused scientific gatherings dedicated to cutaneous lymphomas, including cutaneous T-cell lymphoma (CTCL). The meeting brings together leading dermatologists, hematologist-oncologists, translational researchers, and academic investigators from major
This year's workshop is expected to convene dozens of key opinion leaders and clinical investigators from leading academic institutions, with program sessions covering:
- Novel molecular diagnostics and biomarkers
- Radiology and digital pathology advancements
- Emerging therapies for CTCL
- Future clinical and research directions in cutaneous lymphoma
The workshop format emphasizes small-group discussions and direct interaction among experts, creating an environment where physicians and researchers can exchange insights about evolving treatment paradigms and clinical experience.
Citius Oncology's team will participate in the meeting to engage with clinicians and researchers regarding the treatment landscape for CTCL and discussions regarding clinical experience with LYMPHIR™ (denileukin diftitox-cxdl) which Citius Oncology recently launched in the
"Our participation in the USCLC Workshop reflects our commitment to engaging directly with the leading clinicians who treat patients with cutaneous lymphoma," said Leonard Mazur, Chairman and CEO of Citius Pharmaceuticals. "The USCLC community represents many of the foremost experts and practitioners in CTCL care, and we look forward to productive scientific discussions regarding treatment experience, patient selection, and emerging opportunities to improve outcomes."
About the USCLC Annual Workshop
The USCLC Annual Workshop is organized by the United States Cutaneous Lymphoma Consortium, a collaborative network of leading
USCLC is the only organization in America where professionals from the collaborating disciplines of dermatology, medical oncology, radiation oncology and pathology can exchange ideas and practice tips, discuss, plan and execute scientific collaborations, develop new educational tools, and help shape the research agenda in cutaneous lymphomas. USCLC was created with the express purpose of breaking communication barriers, encouraging "outside-the-box" thinking, and fostering and supporting innovative ideas regarding the treatment and research relating to cutaneous lymphomas. The key initiatives of USCLC are a national registry, a virtual tissue repository, and a clinical trials network.
About LYMPHIR™ (denileukin diftitox‑cxdl)
LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin (DT) fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.
In 2021, denileukin diftitox received regulatory approval in
About Citius Oncology, Inc.
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; early-stage clinical data may not be predictive of results from larger or later-stage studies; our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to maintain Nasdaq's continued listing standards; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
LYMPHIR™ (denileukin diftitox‑cxdl)
INDICATION
LYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
IMPORTANT SAFETY INFORMATION
BOXED WARNING: CAPILLARY LEAK SYNDROME
Capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity.
WARNINGS AND PRECAUTIONS
Capillary Leak Syndrome
LYMPHIR can cause capillary leak syndrome (CLS), including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin <3 g/dL. These symptoms were not required to occur simultaneously to be characterized as capillary leak syndrome.
As defined, CLS occurred in
Regularly assess patients for weight gain, new onset or worsening of edema, dyspnea, and hypotension (including orthostatic changes). Monitor serum albumin levels prior to the initiation of each cycle of therapy and more often as clinically indicated.
Withhold, reduce dose, or permanently discontinue based on severity. If LYMPHIR is withheld, resume LYMPHIR following resolution of CLS and when serum albumin is greater than or equal to 3 g/dL.
Visual Impairment
LYMPHIR can cause serious visual impairment, including changes in visual acuity and color vision. In the pooled population across 3 clinical trials, visual impairment occurred in
Perform baseline ophthalmic examination and monitor as clinically indicated. If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, or blurred vision, refer for ophthalmologic evaluation.
Withhold LYMPHIR until visual impairment resolves or permanently discontinue based on severity.
Infusion-Related Reactions
LYMPHIR can cause serious infusion-related reactions. Infusion-related reactions were reported in
Premedicate patients for the first three cycles prior to starting a LYMPHIR infusion. Monitor patients frequently during infusion. For Grade 2 or higher infusion reactions, premedicate at least 30 minutes prior to each subsequent infusion with a systemic steroid for at least 3 cycles.
Interrupt or discontinue LYMPHIR based on severity. Institute appropriate medical management.
Hepatotoxicity
LYMPHIR can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in
Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold, reduce dose, or permanently discontinue LYMPHIR based on severity.
Embryo-Fetal Toxicity
Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to the initiation of LYMPHIR. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 7 days following the last dose of LYMPHIR.
ADVERSE REACTIONS
The most common adverse reactions (≥
USE IN SPECIFIC POPULATIONS
Pregnancy
Risk Summary
Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman. There are no available data on the use of LYMPHIR in pregnant women to evaluate for a drug-associated risk. No animal reproductive and developmental toxicity studies have been conducted with denileukin diftitox.
Denileukin diftitox-cxdl causes depletion of regulatory T lymphocytes (Treg), immune activation, and capillary leak syndrome, compromising pregnancy maintenance. Advise pregnant women of the potential risk to a fetus.
In the
Lactation
Risk Summary
No data are available regarding the presence of denileukin diftitox-cxdl in human milk, the effects on the breastfed child, or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with LYMPHIR and for 7 days after the last dose.
Females and Males of Reproductive Potential
Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman.
Pregnancy Testing
Verify the pregnancy status of females of reproductive potential prior to initiating LYMPHIR.
Contraception
Females
Advise females of reproductive potential to use effective contraception during treatment with LYMPHIR and for 7 days after the last dose.
Infertility
Males
Based on findings in rats, male fertility may be compromised by treatment with LYMPHIR. The reversibility of the effect on fertility is unknown.
Pediatric Use
Safety and effectiveness of LYMPHIR in pediatric patients have not been established.
Geriatric Use
Of the 69 patients with Stage I-III r/r CTCL who received LYMPHIR, 34 patients (
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Citius Oncology at 1-844-459-6744.
Please read Important Safety Information and full Prescribing Information, including Boxed WARNING, for LYMPHIR.
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-oncology-to-participate-in-usclc-annual-workshop-2026-highlighting-lymphir-in-discussions-with-leading-cutaneous-lymphoma-experts-302723119.html
SOURCE Citius Oncology, Inc.
FAQ
What is Citius Oncology announcing for CTOR at the USCLC Annual Workshop on March 26, 2026?
How might CTOR’s presence at the USCLC Workshop affect LYMPHIR™ awareness among CTCL specialists?
Will Citius Oncology (CTOR) present clinical data on LYMPHIR™ at the USCLC Workshop?
Where and when will CTOR representatives meet clinicians at the USCLC Annual Workshop 2026?
What topics related to CTCL will Citius Oncology (CTOR) engage on at the USCLC Workshop?
